MedPath

GANCICLOVIR

These highlights do not include all the information needed to use GANCICLOVIR INJECTION safely and effectively. See full prescribing information for GANCICLOVIR INJECTION. GANCICLOVIR INJECTION, for intravenous useInitial U.S. Approval: 1989

Approved
Approval ID

26361de8-39b5-4266-90f6-2b307940135d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 6, 2017

Manufacturers
FDA

EXELA PHARMA SCIENCES, LLC

DUNS: 831274399

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

GANCICLOVIR

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51754-2500
Application NumberNDA209347
Product Classification
M
Marketing Category
C73594
G
Generic Name
GANCICLOVIR
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateSeptember 19, 2017
FDA Product Classification

INGREDIENTS (4)

GANCICLOVIRActive
Quantity: 2 mg in 1 mL
Code: P9G3CKZ4P5
Classification: ACTIB
SODIUM CHLORIDEInactive
Quantity: 8 mg in 1 mL
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GANCICLOVIR - FDA Drug Approval Details